Accelerate Diagnostics Q3 2023 Earnings Report

Accelerate Diagnostics EPS Results

• Actual EPS: -$0.92
• Consensus EPS: -$0.94
• Beat/Miss: Beat by +$0.02
• One Year Ago EPS: N/A

Accelerate Diagnostics Revenue Results

• Actual Revenue: $3.30 million
• Expected Revenue: $3.60 million
• Beat/Miss: Missed by -$300.00 thousand
• YoY Revenue Growth: N/A

Accelerate Diagnostics Announcement Details

• Quarter: Q3 2023
• Date: 11/9/2023
• Time: N/A

Accelerate Diagnostics (NASDAQ:AXDX), an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.